Dianthus Therapeutics is advancing its challenge for the increasingly competitive generalized myasthenia gravis (gMG) market, outlining plans to move into phase 3 on the back of hits in a midphase ...

Treatment with darovasertib resulted in robust ocular tumor shrinkage, lower simulated radiation doses to the eye and meaningful visual gains and reduced long-term risk of blindness for patients in ...

Wednesday Season 2 Part 2 rolled out on September 3, 2025, on Netflix. Part 1 had ended with Wednesday and Tyler's tense confrontation in the Willow Hills psychiatric hospital. Wednesday plummeted out ...

The U.S. Senate's work on the crypto industry's top policy priority — a bill to establish the regulatory workings of crypto markets in the U.S. — advanced further on Friday with the private ...

Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to Dupixent, according to analysts at Leerink Partners. Sanofi’s ...

CAPITOLA — Costs are rising as a project along Highway 1 near Capitola and Aptos progresses, prompting the local transportation agency helping lead the effort to fork over millions of dollars more to ...

KENOSHA COUNTY, Wis. (CBS 58) -- A man found guilty of setting his girlfriend on fire in Salem Lakes back in 2023 has learned his fate. In court on Thursday, Sept. 4, a judge sentenced 38-year-old ...

A lakefront mansion listed for more than $30 million in a Chicago suburb has reportedly set a record with its sale price after more than a year on the market. The Winnetka estate known as the "Windsor ...

EXCLUSIVE: Welcome to Le Lotus Blanc — The White Lotus creator Mike White and HBO have zeroed in on France as location for the upcoming fourth season of the hit murder mystery comedy-drama series, ...

Netflix’s plan to turn a shuttered Army base into a Hollywood-style studio moved forward this week as local officials approved the massive second phase of the $903 million project. The newly approved ...

A phase 3 trial of Sanofi’s eczema prospect amlitelimab has hit its primary and key secondary endpoints. Yet, with the data falling short of analyst expectations, shares in the company opened down 9% ...